10 results about "Diagnostic substance" patented technology

The present invention relates to a method for preparing Gram-negative bacterial outer membrane-derived nanovesicles (OMNVs) and uses thereof. Additionally, the present invention provides a method for treating or diagnosing cancer using OMNVs. Furthermore, the present invention provides a method for delivering therapeutic or diagnostic substances to target cells or tissues by loading them into OMNVs. Also, the present invention provides a method for preventing and treating various diseases, including cancer and bacterial / viral infections, by co-administering OMNVs with antigens or administering OMNVs expressing antigens.

The present invention relates to a method for preparing Gram-negative bacterial outer membrane-derived nanovesicles (OMNVs) and uses thereof. Additionally, the present invention provides a method for treating or diagnosing cancer using OMNVs. Furthermore, the present invention provides a method for delivering therapeutic or diagnostic substances to target cells or tissues by loading them into OMNVs. Also, the present invention provides a method for preventing and treating various diseases, including cancer and bacterial / viral infections, by co-administering OMNVs with antigens or administering OMNVs expressing antigens.

In one aspect, a composition is described herein. The composition described herein includes a nanoparticle, a therapeutic species, and a linker that couples the nanoparticle to the therapeutic species. The linker that couples the nanoparticle to the therapeutic species comprises a Diels-Alder cycloaddition reaction product. Additionally, in some embodiments, the nanoparticle is a core-shell-shell metal nanoparticle.

Proposed is a blood-brain barrier penetrating drug delivery system in which sialyllactose, which can penetrate the blood-brain barrier, is linked to a drug. The drug delivery system can deliver low-molecular weight small molecule drugs and high-molecular weight antibodies to the brain, and thus can be applied to various types of brain disease therapeutic agents or diagnostic substances.

The present invention relates to a method for preparing nanovesicles (OMNV) derived from the outer membrane of Gram-negative bacteria and uses thereof. In addition, the present invention provides a method of treating or diagnosing cancer using OMNV. Furthermore, the present invention provides a method of delivering therapeutic or diagnostic substances to target cells or target tissues by loading these substances into the OMNV. In addition, the present invention provides a method for preventing and treating various diseases, including cancer and bacterial / viral infections, by co-administering OMNV with an antigen or administering an antigen-expressing OMNV.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a core-shell-shell metal nanoparticle.

The invention relates to a container (1) comprising a wall (2) made of glass delimiting a cavity (3) to accommodate a substance, particularly for a pharmaceutical or diagnostic substance, the glass wall (2) having an internal face (4) situated facing the accommodating cavity (3), the container (1) being characterized in that the wall (2) is made of soda-lime glass, the internal face (4) forming a bare glass surface intended to come into direct contact with the substance, the glass wall (2) having an atomic fraction of sodium, measured by X-ray-induced photoelectron spectrometry, which is less than or equal to 4 at. % down to a depth of at least 200 nm from the surface of the inner face (4).

FIELD: neurology; laboratory diagnostics.SUBSTANCE: used for the differential diagnosis of Parkinson's disease not associated with mutations in the GBA1 gene, and multiple system atrophy. The patient's peripheral venous blood is collected, from which mononuclear cells are isolated by gradient centrifugation, followed by their differentiation into a primary culture of macrophages in the presence of the macrophage colony-stimulating growth factor M-CSF to ensure proliferation and differentiation of monocytes into mature macrophages. The obtained blood macrophage cells are applied to 903 filter cards at a concentration of 2×106 cells / ml. Whatman 903 Sample Collection Cards can be used as 903 filter cards. The activity of lysosomal enzymes is determined: glucocerebrosidase GCase, alpha-galactosidase GLA, acid sphingomyelinase ASMase, galactosylceramidase GALC by high-performance liquid chromatography in combination with tandem mass spectrometry. The value of the canonical linear discriminant function CLDF is calculated using the stated formula. If the value of CLDF is ≥ 43.44, the patient is diagnosed with multiple system atrophy. If the value of CLDF is < 43.44, Parkinson's disease is diagnosed in patients who do not have a mutation in the GBA1 gene.EFFECT: method enables reliable and accurate differential diagnosis of Parkinson's disease and multiple system atrophy by assessing the activity of lysosomal enzymes.2 cl, 2 dwg, 2 ex

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

The invention relates to an application of LncRNA NEAT1 as a diagnostic substance of Parkinson's disease. Specifically, the LncRNA NEAT1 is used as a marker for diagnosing the Parkinson's disease so as to further diagnose whether the structure and the function of a midbrain nigra region are normal or not and whether the midbrain nigra region suffers from the Parkinson's disease or not, and the LncRNA NEAT1 can be used for developing a diagnostic agent or a kit related to the Parkinson's disease. The invention finds that the LncRNA NEAT1 can be used as a marker for diagnosing the Parkinson's disease for the first time.